secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-071966
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio to file BLA for rese-cel in myositis in 2027 after FDA alignment; cash $131.8M
--------------------------------------------------------------------------------

- FDA aligned on two registrational cohorts for rese-cel in myositis (~15 patients each, 26-week primary endpoint); BLA submission expected in 2027.
- RMAT designation granted for rese-cel in myositis, enabling Fast Track/Breakthrough benefits and expedited BLA review.
- Cash and equivalents $131.8M at March 31, 2025, down from $164M at Dec 31, 2024; funding into first half 2026.
- FDA registrational discussions for SLE/LN anticipated in 3Q25; for systemic sclerosis in 4Q25.
- Three oral presentations of rese-cel data in myositis, SLE/LN, and systemic sclerosis at EULAR 2025 in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025071966/0000950170-25-071966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025071966/caba-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer